Bluebird Bio Collaborates with Forty Seven to Evaluate Antibody Conditioning Regimen in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy
Bluebird Bio’s Zynteglo Receives CHMP’s Positive Opinion for Conditional Marketing for Patients with Transfusion-Dependent β-Thalassemia (TDT) without β0/β0 Genotype
Shots:
- The collaboration will lead to evaluation of Forty Seven’s FSI-174 + magrolimab in combination with Bluebird’s ex vivo lentiviral vector hematopoietic stem cell (LVV HSC) gene therapy platform
- The focus of the collaboration is to develop gene therapy with reduced toxicity and will initially target diseases having the potential to be corrected with transplantation of autologous gene-modified blood-forming stem cells
- FSI-174 is mAb targeting cKIT while magrolimab is a mAb targeting CD47, currently being evaluated in P-II clinical study to treat cancer and other indications including myelodysplastic syndrome, acute myeloid leukemia, diffuse large B cell lymphoma and follicular lymphoma
Click here to read full press release/ article | Ref: Bluebird Bio | Image: Twitter